{
    "organizations": [],
    "uuid": "04a636aa19fa1d7b561489649beb6c9b273e764d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ohr-pharmaceutical-q1-loss-per-sha/brief-ohr-pharmaceutical-q1-loss-per-share-0-07-idUSASB0C5RO",
    "ord_in_thread": 0,
    "title": "BRIEF-Ohr Pharmaceutical Q1 Loss Per Share $0.07",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Ohr Pharmaceutical Inc:\n* OHR PHARMACEUTICAL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.07 * OHR PHARMACEUTICAL - ‍BOARD HAS ENGAGED ROTH CAPITAL MARKETS, TO ADVISE BOARD AND MANAGEMENT, TO ASSIST IN PURSUING RANGE OF STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-15T05:32:00.000+02:00",
    "crawled": "2018-02-15T20:59:07.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ohr",
        "pharmaceutical",
        "inc",
        "ohr",
        "pharmaceutical",
        "report",
        "fiscal",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "ohr",
        "pharmaceutical",
        "engaged",
        "roth",
        "capital",
        "market",
        "advise",
        "board",
        "management",
        "assist",
        "pursuing",
        "range",
        "strategic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}